Abstract Backgrouud: Care for patients with colon and rectal cancer has improved in the last twenty years however stili considerable variation exists in cancer management and outcome between European countries. Therefore, EURECCA, which is the acronym ofEuropean Registration of cancer care, is aiming at defining core treatment strategies and developing a European audit structure in order to improve the quality of care for all patients with colon and rectal cancer. In December 2012 the first multidisciplinary consensos conference about colon and rectum was held looking for moltidisciplinary consensos. The expert panel consisted of representatives of Eoropean scientific organisations in volved in cancer care of patients with colon and rectal cancer and representatives of national colorectal registries. , as well as delega tes from national registries or aodits. Experts commented and voted on the two web-based online voting rounds before the meeting (between 4th and 25th October and between the 20th November and 3rd December 2012) as well as one online round after the meeting (4th-20th March 2013) and were invited to lecture on the subjects during the meeting (13th-15th December 2012). The senterrees in the consensos document were available doring the meeting and a televoting round doring the conference by all participants was performed. All sentences that were voted on are available on the EURECCA website www.canceraudit.eu. The consensus document was divided in sections describing evidence based algorithms of diagnostics, pathology, sorgery, medical oncology, radiotherapy, and follow-up where applicable for treatment of colon cancer, rectal cancer and stage IV separately. Consensos was achieved using the Delphi method.
Methods:

Results:
The total nomber of the voted sentences was 465. All chapters were voted on by at least 75% of the experts. Of the 465 sentences, 84% achieved large con~ensos, 6% achieved moderate consensus, and 7% resolted in minimum consensos, Only 3% was disagreed by more than 50% of the members.
Conclusions:
It ís feasible to achieve European Consensus on key diagnostic and treatment issoes osing the Delphi method. This consensus embodies the expertise of professionals from all disciplines involved in the care for patients with colon and rectal cancer. Diagnostic and treatment algorithms were developed to implement the current evidence and to define core treatment guidance for moltidisciplinary team management of colon and rectal cancer throughoot Europe. 3 In short>' we invited a multidisciplinary expert panel consisting of representa ti ves ofEuropean scientific organisations involved in providing cancer care to colon and rectal cancer patients, in arder to secure a :firm basis to reach the health professionals in the field.
The mission of the European CanCer Organisation (ECCO) aims al 'Every patient deserves the bes! treatment there is'. To optimise cancer care for patients with colon and rectal cancer, one of the key challenges is to strive for optimal multidisciplinary management of outcome besides reaching a European consensus. High incidence and potentially high curability of colon and rectal cancer accentuate that these patients deserve full attention and effort of a multidisciplinary team both befare neoadjuvant treatment or primary surgery as well as after surgery to decide on treatment strategies.
The EUROCARE project, a European Union project to assemble survival data from population-based cancer registries, showed wide variation in rectal and colon cancer 5-year cumulative survival between different European countries in the nineties . .,_. Due to nonacceptable results, severa! countries started quality registries and subsequently quality programmes were initiated based on these reports. The different features ofhealth care in Europe were explored and revealed that there is still a wide diversity of national guidelines and routine clinical practico and that every country has a different health care system, infrastructure and a different availability of registration of population based data."-'
Since the beginning ofthe 1990s treatment of coloreetal cancer has changed substantial!y. At present, many countries have access to national and intemational guidelines? Adherence to guidelines is not always explored or monitored; improvements in securing patterns of care are still ahead. Ideally, treatment decisions are nowadays made preoperatively and postoperatively in multidisciplinary boards. While Iater reports of EUROCARE showed that although survival was improving, inter-country variation is still r_rsisting, suggesting room for further improvement. 5 • 1 Even in high-income countries with well established guidelines and a similar healthcare structure, the difference in outcome is unexplained and vast.
11 Highly relevan! changos in the therapeutic approach have taken place in recen! years such as the implementation of the total mesorectal excision (TME)-technique for rectal cancer surgery.' 4 Another example of progress is preoperative treatment including radiotherapy and chemo radiotherapy for patients with rectal cancer and the incorporation of adjuvant chemotherapy for patients with colon cancer. "-17 In the field of diagnostic imaging, primary staging has been improved, by introducing magnetic resonance imaging (MRI) in the preoperative work-up for rectal cancer 18 
Methodology
Consensus was achieved by the Delphi Method using online web-based voting by experts and televoting Abbreviations: CT, computed tomography; :M:RI, magnetic resonance imaging; PET, positron emission tomography; 'INM, classification of malignant tumours; LN, lyrnph node; RO, no residual tumour; T4 Tumour. invasion ofother organs:; TIS Tumour, carcinoma in situ; sml, classification by Kudo; When less than one~third ofthe submucosa is invaded the stage is sml, and ifmore than two~ thirds is invaded the stage is sm3, while stage sm2 is intennediate with invasion of cancer into the middle third. Sml is when the depth of invasion is less ~1 mm or 1000 ¡.un from the muscularis mucosae. EAES, European Association for Endoscopic Surgery; ERAS, enhanced recovery after surgery; CEA, carcinoembryonic antigen; IviRF, meso rectal fascia; CRM, circumferentiai resection margin; RT, radiation therapy,,Gy, gray; RCT, chemoradiation; TME, total mesorectal excision. .The sentences in the consensus document were available during the meeting anda televoting round during the conference by all participants was performed. Al! sentences that were voted on are available on the EURECCA website www.canceraudit.eu.
The consensus document was divided in sections describing evidence based algorithms of diagnostics, pathology, surgery, medica! oncology, radiotherapy, and follow-up where applicable for treatment of colon cancer, rectal cancer and on stage N separately.
Results.
The Thhd Consensus Conference on Colon and Rectum, Pemgia, developed the follmving rnission statements;
On audits and research
patient deserves the best. We need to continually review what is the best treatment, identify over and under-treatment, and determine the best care. We know that by working in a multidisciplinary environment together with specialist nurses and the patient, progress can be made. Examples of quality care treatment approaches discussed during the meeting are summarised in Table l.
On quality of care
Given the ímportance of each entity within the colorectal cancer care process in determining outcome (surgery, pathology, diagnostic imaging (in staging and restaging), radiotherapy and chemotherapy), quality assurance programmes including education and training programmes should become mandatary for colon and rectal cancer services to pro vide the best quality of care. There is a need for accessible and transparent structures for cancer care in Europe.
Evidence based multidisciplinary management guidelines should be defined at national and European levels \vith the consensus of healthcare professionals, patient organisations and policy makers.
Concluding remarks
The Third Consensus Conference on colon and rec-. tum held in December 2012 achieved large consensus in 84% of the sentences proposed, meaning that more than 95% of the experts agreed on these sentences. Reaching consensus is deemed feasible and achievable in a large number ofkey items related to diagnosis, staging and treatment using the Delphi method. The challenge remains to assess whether this new consensus reaches the field and will be practiced by physicians across Europe, because stilllarge variations exist in clinical practice across Europe. EURECCA is a platform to assess clínica! practice and quality, and to explore the relationship with survival. Also, different scientific societies and stakeholders could work together in arder to build a BU consensus in one of the most frequent cancers diagnosed in European countries.
Contlict of interest statement
National registries and audits are importan! to improve colorectal cancer survival. Definitions and guidelines should be comparable across Europe. Combining large national datasets can identify 'best practices'. Both randomÍsed controlled trials and observational studies of large registries (national or European) are needed to identify key factors for the best colon and rectal cancer care. The strengths of large observational studies are related to providing outcome data on subgroups that are generally not included in clinical trials such as patients with co-morbidities and elderly. This will help professionals to optimise treatment strategies for these specific subgroups.
On behalf of the authors we state that the consensus meeting was possible due to a non-restrictive uncondi-. tional Grant from ESSO. No other conflict of interest for this publication.
